LOGO
LOGO

Quick Facts

Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Neurocrine Biosciences, Inc. (NBIX) Monday reported new positive data from the Phase 3 CAHtalyst Adult study of Crenessity in adults with classic congenital adrenal hyperplasia (CAH).

Congenital adrenal hyperplasia (CAH) is a group of genetic disorders that affect the Congenital adrenal glands.

One-year data from CAHtalyst Adult study showed lasting reductions in the dose of glucocorticoid, a class of steroid hormones, and improvement in clinical outcomes in adults with classic CAH. the results build upon previously reported one-year data from CAHtalyst Pediatric study.

These results were presented at the Endocrine Society's Annual Meeting, ENDO 2025.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.